ProNAi Therapeutics Inc.
This article was originally published in Start Up
The potentially profitable idea in ProNAi's portfolio is an approach the drug development community overlooked--taking direct aim at a diseased cell's DNA in order to suppress a disease pathway. ProNAi will use nucleic acid interfering technology (DNAi) to develop drugs across a broad spectrum of genetic diseases, but it intends to file its first INDs for prostate cancer and non-Hodgkin's lymphoma.
You may also be interested in...
If 2006 was a breakout year for RNAi the concept, then 2007 could be a breakout year for RNAi drug development itself. In the past few years there has been a surge of newcomers to the space, in some cases sporting high-quality venture backers and boldfaced names in RNAi. Some companies have decided to play ball with the industry leaders, sublicensing Alnylam's IP around their chosen targets, for example; others have filed their own IP-either outside the Alnylam and Merck umbrellas or putting them on a relatively slow-motion collision course with the two power brokers; still others have argued that patenting novel delivery technologies will provide them with the necessary edge in licensing negotiations, should they come about, or with pharmaceutical partners.
New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.